SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nexell Therapeutics Inc – ‘8-A12G’ on 6/26/97

As of:  Thursday, 6/26/97   ·   Accession #:  864009-97-18   ·   File #:  0-28124

Previous ‘8-A12G’:  None   ·   Next:  ‘8-A12G/A’ on 3/17/00   ·   Latest:  ‘8-A12G/A’ on 12/4/02

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size

 6/26/97  Nexell Therapeutics Inc           8-A12G                 1:6K

Registration of a Class of Securities   —   Form 8-A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-A12G      Form 8-A                                               3     11K 


Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 1. Description of Registrant's Securities to be Registered
"Item 2. Exhibits
8-A12G1st Page of 3TOCTopPreviousNextBottomJust 1st
 

As filed with the Securities and Exchange Commission on April 16, 1997 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VIMRx PHARMACEUTICALS INC. -------------------------- (Exact name of registrant as specified in its charter) Delaware 06-1192468 --------- ---------- (State of incorporation or organization) (I.R.S. Employer Identification No.) 2751 Centerville Road, Wilmington, Delaware 19808 ------------------------------------------- ----- (Address of principal executive offices) (Zip Code) If this Form relates to the registration If this Form relates to the of a class of debt securities and is registration of a class of debt effective upon filing pursuant to General securities and is to become Instruction A(c)(1) please check the effective simultaneously with the following box. [_] effectiveness of a concurrent registration statement under the Securities Act of 1933 pursuant to General Instruction A(c)(2) please check the following box. |_| Securities to be registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which to be so Registered Each Class is to be Registered ------------------- ------------------------------ Not Applicable Not Applicable ------------------- ------------------------------ Securities to be registered pursuant to Section 12(g) of the Act: Common Stock Subscription Warrants ---------------------------------- (Title of Class) Page 1 of 3 Pages
8-A12G2nd Page of 3TOC1stPreviousNextBottomJust 2nd
Item 1. Description of Registrant's Securities to be Registered. Each Common Stock Subscription Warrant (collectively, the "Warrants") entitles the registered holder to purchase one share of Common Stock at $1.50 per share at any time through June 20, 2006, the expiration date of the Warrants. The exercise price of the Warrants and the number and kind of shares of Common Stock or other securities and property issuable upon exercise of the Warrants are subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or capitalization of, the Common Stock, or the sale of Common Stock at less than the market price of the Common Stock other than upon exercise of options or warrants outstanding on or prior to June 21, 1996 (the date the Warrants were issued). Upon notice to the Warrantholders, the Company has the right to reduce the exercise price or extend the expiration of the Warrants. The Warrants are not redeemable. The Warrants were issued pursuant to a warrant agreement between VIMRx Pharmaceuticals Inc. (the "Registrant") and American Stock Transfer & Trust Company, the warrant agent (the "Warrant Agent"), and are evidenced by warrant certificates in registered form. The Warrants do not confer upon the holder any voting or other rights of a stockholder of the Company. The Warrants may be exercised upon surrender of the Warrant certificate evidencing such Warrants on or prior to the expiration date of such Warrants at the offices of the Warrant Agent with the form of "Election to Purchase" on the reverse side of the Warrant certificate completed and executed as indicated, accompanied by payment of the full exercise price (by certified check payable to the order of the Warrant Agent) for the number of Warrants being exercised. The Warrants are not redeemable. Item 2. Exhibits. 4.4 Copy of Warrant Agreement dated June 17, 1996 between the Registrant and the Warrant Agent with Form of Warrant Certificate (1). ------------------------ (1) Filed as the same numbered Exhibit to the Registrant's Registration Statement on Form S-3 (File No. 333-25469) and incorporated herein by reference thereto.
8-A12GLast Page of 3TOC1stPreviousNextBottomJust 3rd
SIGNATURE Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized. VIMRx PHARMACEUTICALS INC. (Registrant) By: /s/ Richard L. Dunning Richard L. Dunning, President and Chief Executive Officer Dated: June 18, 1997

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-A12G’ Filing    Date First  Last      Other Filings
6/20/062None on these Dates
Filed on:6/26/97
6/18/973
4/16/971
6/21/962
6/17/962
 List all Filings 
Top
Filing Submission 0000864009-97-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 19, 6:11:43.2am ET